Drug name - Oraverse
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7229630 | SEPTODONT HOLDING | Stabilized formulations of alpha adrenergic receptor antagonists and the uses thereof |
Jun, 2023
(8 months from now) | |
| US7569230 | SEPTODONT HOLDING | Stabilized formulations of alpha adrenergic receptor antagonists and the uses thereof |
Oct, 2023
(1 year, 14 days from now) | |
| US7575757 | SEPTODONT HOLDING | Stabilized formulations of alpha adrenergic receptor antagonists and the uses thereof |
Apr, 2025
(2 years from now) | |
Drugs and Companies using PHENTOLAMINE MESYLATE ingredient
Treatment: A method of reversing soft-tissue anesthesia i.e. anesthesia of the lip and tongue, and the associated functional deficits resulting from an intraoral submucosal injection of a local anesthetic
Dosage: INJECTABLE;INJECTION
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| 0.4MG/1.7ML | INJECTABLE;INJECTION | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.